A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

Study Overview

• Status: Recruiting
• Conditions: Neoplasms; Neoplasm Metastasis; Non-Small-Cell Lung Cancer
• Intervention / Treatment: Drug: EMB-01

Detailed Description

This is a first-in-human (FIH), open-label, Phase I/II study of EMB-01, a bispecific Epidermal growth factor receptor (EGFR) and c-Mesenchymal-Epithelial Transition (cMet) antibody, in patients with advanced solid tumors who have progressed on available standard therapies or for which no standard therapy exists. The study consists of two parts: Phase I (dose escalation) and Phase II (cohort expansion). The study is planning to recruit tentatively 33-66 subjects with advanced/metastatic solid tumors in phase I and approximately 42-120 subjects with EGFR mutant and/or cMET aberrated NSCLC who have progressed on or are intolerant to standard treatment(s) (including platinum-based therapy) will be enrolled at the RP2D(s) in phase II part of the study. In phase II, patients will be assigned to five groups according to their molecular status at baseline. The trial will consist of molecular pre-screening period (Phase II only), clinical screening period (-28 to -1 days), treatment cycles (each cycle is 28 days, maximum up to 2 years), and safety follow-up period (30 days after the last dose).

• Study Type: Interventional
• Enrollment (Estimated): 186
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Xiaodong Sun, MD; Phone Number: +86-21-61043299; Email: xdsun@epimab.com
• Study Contact Backup: Name: Xuemei Xie; Phone Number: +86-21-61043299; Email: xmxie@epimab.com

Study Locations

• China
  • Guang Dong
    • Guangzhou, Guang Dong, China, 510080
      • Recruiting
      • Guangdong General Hospital
  • Shanghai
    • Shanghai, Shanghai, China, 200030
      • Recruiting
      • Shanghai Chest Hosptial
• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Recruiting
      • Dana-Farber Cancer Institute
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Recruiting
      • Barbara Ann Karmanos Cancer Institute
  • Ohio
    • Canton, Ohio, United States, 44718
      • Recruiting
      • Gabrail Cancer Center Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Molecular Pre-screening Inclusion criteria (Phase II only)

1. The patient must sign the molecular pre-screening Inform Consent to allow for the molecular pre-screening process. All patients must have documented evidence of EGFR and/or cMet aberrations.

Screening Inclusion Criteria

1. Able to understand and willing to sign the Informed Consent Form (ICF).

2. Histologically/cytologically confirmed advanced/metastatic solid tumors with measurable disease [Response Evaluation Criteria in Solid Tumors (RECIST) v1.1]:

   Phase I: advanced/metastatic solid tumors including but not limited to NSCLC, colorectal cancer, gastric cancer and liver cancer refractory to standard therapy or for which no standard therapy is available or accessible.

   Phase II: Advanced/metastatic NSCLC Patients have confirmed EGFR mutant and/or cMET aberration, and have progressed after standard treatment (including platinum-based therapy) or are intolerant to standard treatment. Additionally, patients with T790M mutation have received FDA/Health Authority approved therapies (if accessible) for this indication (i.e., osimertinib) and have progressed or became intolerant.

   A patient who has refused all currently available therapy is allowed to enroll, but must be documented in the source record.

3. Must have adequate organ function.

4. Regarding prior anti-tumor therapy:

   1. Must have stopped treatment at least 4 weeks or within 5 half-lives.
   2. Generalized radiation therapy must have stopped 3 weeks before first dose of EMB 01, or local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01.
   3. Patients must have recovered to ≤Grade 1 from the adverse effects of such above treatment before beginning study treatment.
5. Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception starting from screening period and continue throughout the study treatment and for 3 months.
6. ECOG score 0 or 1 for phase I, and ≤2 for phase II.

Exclusion Criteria:

Molecular Pre-screening Exclusion Criteria (Phase II only)

Subject who meets any of the follow criteria can't be proceeded to clinical screening:

1. Patients who are unwilling to sign the molecular pre-screening ICF.
2. Patients for whom local EGFR and/or cMET data or the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria.

Screening Exclusion Criteria

1. Life expectancy < 3 months.
2. Subject with primacy central nervous system (CNS) malignancy or symptomatic CNS (leptomeningeal or brain) metastases.
3. Pregnant or nursing females.
4. Subjects who have had major surgery within 28 days prior to screening.
5. Serious underlying medical conditions, including but not limited to un-controlled hypertension, other cardiovascular disease or diabetes, ongoing or active infection, psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere the compliance with study treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Dose Escalation-Part 1, Expansion-Part 2; In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered. In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks).

Drug: EMB-01; In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered. In part 2, participants will receive intravenous infusion of EMB-01 at RP2D The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks). Participants may continue to receive study drug until discontinuation criteria are met.; Other Names: FIT-013a

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD) (phase 1 only)	Maximum tolerated dose	cycle 1 (1cycle = 28 days)
Adverse Events (AEs), and Serious Adverse Events (SAEs)	Adverse Events, and Serious Adverse Events	Screening up to follow-up (30 days after the last dose)
Overall Response Rate (ORR) (phase 2 only)	Overall Response Rate	From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Serum Concentration (Cmax)	Maximum Serum Concentration	Through treatment discontinuation: an average of 6 months
Area Under the Plasma Concentration-Time Curve (AUC)	Area Under the Plasma Concentration-Time Curve	Through treatment discontinuation: an average of 6 months
Trough Serum Concentration (Ctrough)	Trough Serum Concentration	Through treatment discontinuation: an average of 6 months
Elimination half-life (t1/2)	Elimination half-life	Through treatment discontinuation: an average of 6 months
Clearance (CL)	Clearance	Through treatment discontinuation: an average of 6 months
Volume of distribution at steady state (Vss)	volume of distribution at steady state	Through treatment discontinuation: an average of 6 months
Accumulation Ratio (AR)	Accumulation Ratio	hrough treatment discontinuation: an average of 6 months
Dose Proportionality	Dose Proportionality	Through treatment discontinuation: an average of 6 months
Anti-Drug Antibodies (ADA)	Anti-Drug Antibodies	Through study completion, an average of 7 months
Duration Of Response (DOR)	Duration Of Response	From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Progression-Free Survival (PFS)	Progression-free survival	Through treatment discontinuation: an average of 6 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacodynamic (Soluble EGFR and cMET concentration)	Pharmacodynamic (Soluble EGFR and cMET concentration)	Through treatment discontinuation: an average of 6 months

Collaborators and Investigators

• Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.
• Collaborators: Covance

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2018
• Primary Completion (Estimated): March 14, 2025
• Study Completion (Estimated): January 15, 2026

Study Registration Dates

• First Submitted: December 26, 2018
• First Submitted That Met QC Criteria: January 6, 2019
• First Posted (Actual): January 9, 2019

Study Record Updates

• Last Update Posted (Actual): May 31, 2023
• Last Update Submitted That Met QC Criteria: May 30, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Human Bispecific antibody,; Epidermal Growth Factor Receptor (EGFR),; c-Mesenchymal-Epithelial Transition (cMet),; Neoplasms, Neoplasm Metastasis,; Non-Small-Cell Lung Cancer (NSCLC), First-in-human,; EMB-01, Tyrosine Kinase Inhibitor (TKI) Resistant
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Neoplastic Processes; Lung Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
• Other Study ID Numbers: EMB01X101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No